The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2018 | Moving beyond monotherapy in HCC
Some hepatocellular carcinoma (HCC) combination regimens including immunotherapy seem to be particularly promising, suggests Arndt Vogel, MD, PhD, of Hannover Medical School, Hannover, Germany, at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany. Prof. Vogel also brings attention to the current lack of suitable biomarkers, which are needed to inform treatment strategies and/or identify mechanisms of resistance.
